Drug Design of GLP-1 Receptor Agonists: Importance of In Silico Methods.

Current Pharmaceutical Design
Smriti Sharma, Vinayak Bhatia

Abstract

Drug design based on degradation-resistant, long-acting Glucagon-like peptide-1 receptor (GLP-1R) agonists for treating type 2 diabetes is attracting a lot of attention. Here, the authors have examined in detail how in silico drug design is aiding in developing novel GLP-1 receptor agonist drugs. Their pharmacotherapy and adverse effects have also been summarized. After the analysis of currently available information on this topic, the authors feel that in silico method is a great auxiliary tool in almost all the experimental studies on GLP-1 receptors and is highly efficient in identifying novel drug molecules that can act as GLP-1 receptor agonists.

Related Concepts

Related Feeds

Cardiovascular Biology of GLP-1

Glucagon-like peptide 1 (GLP-1) plays a role in glucose metabolism, energy homeostasis, and inflammation suppression. GLP-1 receptor signaling has been shown to impact cardiovascular function. This feed focuses on the role of GLP-1 and GLP-1 receptor agonists on cardiovascular biology.

Related Papers

Lancet
Christophe E M De Block, Luc F Van Gaal
JAMA : the Journal of the American Medical Association
Irl B Hirsch
The Medical Letter on Drugs and Therapeutics
The Review of Diabetic Studies : RDS
Theodosios D FilippatosMoses S Elisaf
© 2021 Meta ULC. All rights reserved